RAL plus ABC/3TC — Competitive Intelligence Brief

RAL plus ABC/3TC (RAL plus ABC/3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

RAL plus ABC/3TC (RAL plus ABC/3TC) — Juan A. Arnaiz. This combination uses raltegravir (an integrase inhibitor) plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication through multiple mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RAL plus ABC/3TC TARGET	RAL plus ABC/3TC	Juan A. Arnaiz	phase 3	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
Regimen：BIC+FTC+TAF	Regimen：BIC+FTC+TAF	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Genvoya Crushed Dose	Genvoya Crushed Dose	Johns Hopkins University	marketed	Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Central Institute of Epidemiology, Moscow, Russia · 1 drug in this class
2. Harvard School of Public Health (HSPH) · 1 drug in this class
3. Juan A. Arnaiz · 1 drug in this class
4. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
5. Prism Health North Texas · 1 drug in this class